Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies the side effects and best dose of lapatinib when given together with dabrafenib in treating patients with thyroid cancer that cannot be removed by surgery and has not responded to previous treatment (refractory). Dabrafenib selectively binds to and blocks the activity of v-raf murine sarcoma viral oncogene homolog B (BRAF), which may block the growth of tumor cells which contain a mutated BRAF gene. Lapatinib reversibly blocks the process in which a phosphate group is added to a molecule (phosphorylation) of the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (ErbB2), and the mitogen-activated protein kinase 3 (Erk-1) and mitogen-activated protein kinase 1(Erk-2) and protein kinase B (AKT) kinases. It also blocks cyclin D protein levels in human tumor cell lines. Dabrafenib and lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose of lapatinib that can be used in combination of dabrafenib. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. II. Evaluate potential mechanisms of primary resistance of BRAF mutant thyroid cancer to dabrafenib by performing pathway profiling of tumor biopsies before and while on therapy. III. Obtain preliminary data on the activity of the combination of lapatinib and dabrafenib in BRAF mutant thyroid cancer through imaging. OUTLINE: This is a dose-escalation study of lapatinib. Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 of each cycle. After two weeks of single agent dabrafenib, patients also start receiving lapatinib PO once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo tumor biopsy, blood sample collection, echocardiography (ECHO) or multigated acquisition scan (MUGA), as well as positron emission tomography (PET), computed tomography (CT), or magnetic resonance imaging (MRI) during screening and on study. After completion of study treatment, patients are followed up for 4 weeks and then annually thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01947023
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Active, not recruiting
Phase Phase 1
Start date September 27, 2013
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04061980 - Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer Phase 2
Recruiting NCT04171622 - Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT02393690 - Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Phase 2
Recruiting NCT04693377 - Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial N/A
Active, not recruiting NCT03181100 - Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Phase 2
Withdrawn NCT04731740 - Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT02152995 - Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Phase 2